A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today
On the early morning of 15 July 2025, China Medical System Holdings Limited (CMS) celebrated its secondary listing on the Singapore Exchange Main Board. This strategic move is a significant milestone for CMS, demonstrating its commitment to expanding its market reach in the Asia-Pacific region, particularly in Southeast Asia and the Middle East.
During the listing ceremony, Mr. Lam Kong, Chairman, Chief Executive Officer, and President of CMS, emphasized the importance of this secondary listing in Singapore as part of CMS’s broader Asia-Pacific strategy. He highlighted the company’s evolution over its 33-year journey, from being China’s largest CSO to transitioning into the pharmaceutical sector and finally focusing on innovation, specialized breakthroughs, and internationalization to drive the growth of the ‘New CMS’ model.
By leveraging its integrated ecosystem, CMS aims to establish a new paradigm for Chinese pharmaceutical globalization. Not only does this move facilitate market expansion for CMS products in emerging economies, but it also provides global partners with a comprehensive solution, fueling further growth for the Group.
Looking forward, CMS remains dedicated to advancing its core strategies to solidify the enduring value proposition of the ‘New CMS’ model and sustain its growth trajectory in the evolving pharmaceutical landscape.
